We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioNTech (BNTX)/ Pfizer to Seek FDA Nod for COVID-19 Booster
Read MoreHide Full Article
BioNTech SE (BNTX - Free Report) and its partner pharma giant Pfizer (PFE - Free Report) announced that they are planning to get authorization for a COVID-19 booster vaccine shot, which is a third dose of their currently authorized COVID-19 vaccine BNT162b2, in the United States.
The companies are working on an updated booster shot of BNT162b2 which has the potential to provide higher protection against the new, highly contagious variant of COVID-19, Delta (B.1.617.2). The Delta variant was first found in India, and is rapidly spreading to other parts of the world, increasing the risk of infections across the globe. The variant is now found in more than 100 countries, including the United States.
Per the U.S. Centers for Disease Control and Prevention, the Delta variant has become the most dominant strain in the United States, accounting for majority of new COVID-19 cases in the country. The World Health Organization has warned that Delta will become the globally dominant variant of the coronavirus in the coming months.
Notably, BioNTech/Pfizer announced that a third dose of BNT162b2, administered six months after the second dose, demonstrated a consistent tolerability profile while eliciting high neutralization titers against the wild type and the Beta variant of the virus. As a result, it provides five to 10 times higher protection than after the second dose of BNT162b2.
Importantly, data published in Nature showed that the immune sera obtained shortly after the second dose of BNT162b2 have strong neutralization titers against the Delta variant. BioNTech/Pfizer believe that a third dose of BNT162b2 will boost those antibody titers even higher.
An increase in the number of cases linked to the Delta variant may cause more severe disease, especially among the unvaccinated people, which can lead to more hospitalizations, and potentially result in more deaths.
Shares of BioNTech have skyrocketed 155.1% so far this year against the industry’s decrease of 2.2%.
Image Source: Zacks Investment Research
Presently, apart from BioNTech/Pfizer’s BNT162b2, Moderna’s (MRNA - Free Report) mRNA-1273 and J&J’s (JNJ - Free Report) single-shot COVID-19 vaccine are available in the United States. AstraZeneca’s vaccine (called Vaxzevria in EU), although available in several countries including India, has not yet been launched in the United States.
In early July, J&J announced new data from studies that demonstrated that its one-shot COVID-19 vaccine generated strong neutralizing antibody activity against the Delta variant. In late June, Moderna announced new results from in vitro neutralization studies on sera from individuals vaccinated with its COVID-19 vaccine, mRNA-1273. Data showed that vaccination with mRNA-1273 can produce a neutralizing effect against all COVID-19 variants tested, including Delta.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
BioNTech (BNTX)/ Pfizer to Seek FDA Nod for COVID-19 Booster
BioNTech SE (BNTX - Free Report) and its partner pharma giant Pfizer (PFE - Free Report) announced that they are planning to get authorization for a COVID-19 booster vaccine shot, which is a third dose of their currently authorized COVID-19 vaccine BNT162b2, in the United States.
The companies are working on an updated booster shot of BNT162b2 which has the potential to provide higher protection against the new, highly contagious variant of COVID-19, Delta (B.1.617.2). The Delta variant was first found in India, and is rapidly spreading to other parts of the world, increasing the risk of infections across the globe. The variant is now found in more than 100 countries, including the United States.
Per the U.S. Centers for Disease Control and Prevention, the Delta variant has become the most dominant strain in the United States, accounting for majority of new COVID-19 cases in the country. The World Health Organization has warned that Delta will become the globally dominant variant of the coronavirus in the coming months.
Notably, BioNTech/Pfizer announced that a third dose of BNT162b2, administered six months after the second dose, demonstrated a consistent tolerability profile while eliciting high neutralization titers against the wild type and the Beta variant of the virus. As a result, it provides five to 10 times higher protection than after the second dose of BNT162b2.
Importantly, data published in Nature showed that the immune sera obtained shortly after the second dose of BNT162b2 have strong neutralization titers against the Delta variant. BioNTech/Pfizer believe that a third dose of BNT162b2 will boost those antibody titers even higher.
An increase in the number of cases linked to the Delta variant may cause more severe disease, especially among the unvaccinated people, which can lead to more hospitalizations, and potentially result in more deaths.
Shares of BioNTech have skyrocketed 155.1% so far this year against the industry’s decrease of 2.2%.
Presently, apart from BioNTech/Pfizer’s BNT162b2, Moderna’s (MRNA - Free Report) mRNA-1273 and J&J’s (JNJ - Free Report) single-shot COVID-19 vaccine are available in the United States. AstraZeneca’s vaccine (called Vaxzevria in EU), although available in several countries including India, has not yet been launched in the United States.
In early July, J&J announced new data from studies that demonstrated that its one-shot COVID-19 vaccine generated strong neutralizing antibody activity against the Delta variant. In late June, Moderna announced new results from in vitro neutralization studies on sera from individuals vaccinated with its COVID-19 vaccine, mRNA-1273. Data showed that vaccination with mRNA-1273 can produce a neutralizing effect against all COVID-19 variants tested, including Delta.
Zacks Rank
BioNTech currently has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>